Difference between revisions of "Pacritinib (Vonjo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
From the [http://www.cancer.gov/drugdictionary?CdrID=609888 NCI Drug Dictionary]: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Also, per [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256753/ Hart et al. 2011] pacritinib is a tyrosine kinase inhibitor (TKI) with equipotent activity against FLT3 (IC<sub>50</sub>=22 n) and Janus kinase 2 (JAK2, IC<sub>50</sub>=23 n). | From the [http://www.cancer.gov/drugdictionary?CdrID=609888 NCI Drug Dictionary]: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Also, per [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256753/ Hart et al. 2011] pacritinib is a tyrosine kinase inhibitor (TKI) with equipotent activity against FLT3 (IC<sub>50</sub>=22 n) and Janus kinase 2 (JAK2, IC<sub>50</sub>=23 n). | ||
| − | == | + | ==Diseases for which it is used== |
| + | *[[Myelofibrosis]] | ||
| − | == | + | ==History of changes in FDA indication== |
| − | + | *2022-03-01: Granted accelerated approval for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) [[myelofibrosis]] with a platelet count below 50 x 10<sup>9</sup>/L. ''(Based on PERSIST-2)'' | |
| − | + | ||
| − | + | ==Also known as== | |
| + | *'''Code name:''' SB-1518 | ||
| + | *'''Brand name:''' Vonjo | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
| − | [[Category: | + | [[Category:JAK2 inhibitors]] |
[[Category:Myelofibrosis medications]] | [[Category:Myelofibrosis medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2022]] |
Latest revision as of 11:25, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Also, per Hart et al. 2011 pacritinib is a tyrosine kinase inhibitor (TKI) with equipotent activity against FLT3 (IC50=22 n) and Janus kinase 2 (JAK2, IC50=23 n).
Diseases for which it is used
History of changes in FDA indication
- 2022-03-01: Granted accelerated approval for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 109/L. (Based on PERSIST-2)
Also known as
- Code name: SB-1518
- Brand name: Vonjo